Promising targets for therapy of osteoarthritis: a review on the Wnt and TGF-β signalling pathways

Osteoarthritis (OA) is the most common chronic joint disorder worldwide, with a high personal burden for the patients and an important socio-economic impact. Current therapies are largely limited to pain management and rehabilitation and exercise strategies. For advanced cases, joint replacement surgery may be the only option. Hence, there is an enormous need for the development of effective and safe disease-modifying anti-OA drugs. A strong focus in OA research has been on the identification and role of molecular signalling pathways that contribute to the balance between anabolism and catabolism in the articular cartilage. In this context, most insights have been gained in understanding the roles of the transforming growth factor-beta (TGF-beta) and the Wingless-type (Wnt) signalling cascades. The emerging picture demonstrates a high degree of complexity with context-dependent events. TGF-beta appears to protect cartilage under healthy conditions, but shifts in its receptor use and subsequent downstream signalling may be deleterious in aged individuals or in damaged cartilage. Likewise, low levels of Wnt activity appear important to sustain chondrocyte viability but excessive activation is associated with progressive joint damage. Emerging clinical data suggest some potential for the use of sprifermin, a recombinant forms of fibroblast growth factor 18, a distant TGF-beta superfamily member, and for lorecivivint, a Wnt pathway modulator.

Automated summary

Osteoarthritis is a common chronic joint disorder globally, with limited current therapies focused on pain management and rehabilitation, highlighting the urgent need for effective and safe anti-OA drugs. Research has identified the significance of TGF-beta and Wnt signaling pathways in maintaining the balance of anabolism and catabolism in articular cartilage, with context-dependent complexities influencing outcomes.